Evidence for Use of Teriparatide in Spinal Fusion Surgery in Osteoporotic Patients.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 27923758.
- Also identified by DOI 10.1016/j.wneu.2016.11.135.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Osteoporosis is defined as bone mineral density. A PubMed literature review was performed to review preclinical and clinical evidence for the use of teriparatide in osteoporotic patients undergoing spine fusion surgery. Preclinical studies in animal models show that teriparatide increases spinal fusion rates. Early clinical studies show that teriparatide both increases spinal fusion rates and decreases hardware loosening in the setting of postmenopausal osteoporosis. Ongoing additional trials will help formulate preoperative screening recommendations, determine the optimal duration of preoperative and postoperative teriparatide treatment, and investigate its utility in men.
Medical subject headings
- Fracture Healing
- Osteoporosis
- Spinal Fractures
- Spinal Fusion
- Teriparatide